Abstracts tagged "Disease Activity"

Abstract Number: 128 • 2014 ACR/ARHP Annual Meeting
A Rapid 4- Joint Ultrasonographic Score to Daily Monitoring Disease Activity in Patients with Rheumatoid Arthritis: Validity and Sensitivity to Change
Tomas Cazenave¹, Christian A. Waimann², Gustavo Citera³ and Marcos G. Rosemffet⁴, ¹Junin 519 1ero B, IREP, Buenos Aires, Argentina, ²Rheumatology, Hospital Olavarria, Olavarria, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose Ultrasound has demonstrated to be a sensitivity and specific tool to assess patients with Rheumatoid Arthritis (RA). However, the feasibility of this technology in…
Abstract Number: 2636 • 2014 ACR/ARHP Annual Meeting
Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
John A. Reynolds¹, David W. Ray², Terence O'Neill³, Yvonne Alexander⁴ and Ian N. Bruce^5,6, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose SLE patients have an increased risk of cardiovascular disease (CVD). Vitamin D deficiency has been associated with both CVD risk factors and subclinical CVD…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Paul Studenic¹, Josef Smolen² and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine 3, Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGA
Abstract Number: 1040 • 2014 ACR/ARHP Annual Meeting
Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention
Atsuko Murota¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki³, Rimpei Morita⁴, Akihiko Yoshimura⁴ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IL-16 is a chemoattractant factor that evokes massive infiltration of mononuclear cells in the synovial tissue in patients rheumatoid arthritis (RA). IL-16 concentrations are…
Abstract Number: 679 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort
Jennifer M. Grossman¹, Megan E. B. Clowse², Peter M. Izmirly³, Diane L. Kamen⁴, Alana B. Levine⁵, Meggan Mackey⁶, W. Joseph McCune⁷, Jerry McGwin⁸, David S. Pisetsky⁹, Tammy Utset¹⁰ and Jinoos Yazdany¹¹, ¹Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, Duke University Medical Center, Durham, NC, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Mahasset, NY, ⁷Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁸Biostats, UAB, Birmingham, AL, ⁹Duke University Medical Center, Durham, NC, ¹⁰Internal Medicine/Rheumatology, UC Pritzker Schl of Medicine, Chicago, IL, ¹¹Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with hydroxychloroquine (HCQ) is recommended for all patients with lupus nephritis to prevent further damage and reduce disease manifestations. Some studies suggest…
Abstract Number: 393 • 2014 ACR/ARHP Annual Meeting
Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Celine Vidal¹, Thomas Barnetche², Jacques Morel³, Bernard Combe⁴ and Claire Daien⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁵Hopital Lapeyronie, Montpellier, France
Background/Purpose: Overweight and obesity in patients with rheumatoid arthritis (RA) are rising conditions. Adipose tissue has pro inflammatory properties by producing adipokines which could play…
Abstract Number: 114 • 2014 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists
John J. Cush¹ and Jeffrey R. Curtis², ¹Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ²University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Changes in US rheumatologic practice for rheumatoid arthritis (RA) patients in the past decade have been influenced by novel therapies, increasing disease metric use…
Abstract Number: 2634 • 2014 ACR/ARHP Annual Meeting
A Signal of Improvement in Lupus Disease Activity at 3 Months Predicts Further Valid Improvement at 6 Months
Zahi Touma¹, Dafna D. Gladman², Dominique Ibanez¹ and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: In patients with active disease, physicians look for an early signal in response to treatment to guide their therapeutic decisions. Systemic Lupus…
Abstract Number: 2430 • 2014 ACR/ARHP Annual Meeting
The Impact of Inadequate Health Literacy on Disease Activity in Patients with Rheumatoid Arthritis
Maria Celeste Orozco¹, Maria Florencia Marengo², Christian A. Waimann², Ana Inés Marcos³, Amelia Granel³, Sofia Velez⁴, Federico Zazzetti⁵, Juan C. Barreira⁶, Paula Kohan⁷, Oscar L. Rillo⁸, María Victoria Collado⁹, Graciela Gómez¹⁰, Ricardo V. Juárez¹¹, Veronica Lencina¹², Andrea D'Orazio¹³, Gustavo Rodriguez Gil¹³, Mariana Salcedo¹⁴ and Gustavo Citera¹⁵, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ⁴Rheumatology, Hospital Britanico, Buenos Aires, Argentina, ⁵Hospital Britanico, Buenos Aires, Argentina, ⁶Rheumatology, British Hospital, Buenos Aires, Argentina, ⁷rheumatology, Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁸Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁹Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ¹¹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹²Rheumatology section, Hospital Señor del Milagro, Salta, Argentina, ¹³rheumatology, Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, ¹⁴Consultorio Privado, San Nicolás, Argentina, ¹⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Health literacy is the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. It is being…
Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting
Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Michelle Ormseth¹, Cecilia P. Chung², Joseph F. Solus³, Annette M. Oeser³, Margery A. Connelly⁴, Jim Otvos⁴ and C Michael Stein³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴LipoScience, Inc., Raleigh, NC
Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…
Abstract Number: 1386 • 2014 ACR/ARHP Annual Meeting
Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
I.M. Markusse¹, L. Dirven², Y.P. Goekoop-Ruiterman³, P.a. van der Lubbe⁴, A.J. Peeters⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁸Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Disease flares frequently occur in patients with rheumatoid arthritis (RA). It has been suggested that these may spontaneously remit, in which case targeted treatment…
Abstract Number: 1039 • 2014 ACR/ARHP Annual Meeting
Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity
Ladislav Senolt¹, Klara Prajzlerova¹, Hana Hulejova², David Veigl³, Karel Pavelka¹ and Jiri Vencovsky¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³1st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and subsequent joint damage with systemic manifestations. Interleukin-20 (IL-20) has been…
Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Joan T. Merrill¹, Yong Li², Stephen D. Wax³ and Christopher Tehlirian⁴, ¹Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²R&D Global BioStatistics, EMD Serono, Billerica, MA, ³Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁴EMD Serono, Rockland, MA
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].